



August 12, 2025

Listing Department
BSE LIMITED
P J Towers, Dalal Street,
Mumbai-400 001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: ZYDUSLIFE

Re: Outcome of Board Meeting

Ref.: Disclosures under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")

Dear Sir / Madam,

The Board of Directors ("the **Board**") at their meeting held today i.e. August 12, 2025, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter ended on June 30, 2025.

In this regard, please find enclosed the following:

1. the unaudited financial results (standalone and consolidated) for the quarter ended on June 30, 2025, reviewed by the Audit Committee and taken on record by the Board pursuant to regulation 33 of the Listing Regulations.
2. the limited review reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company ("**Deloitte**") certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2025, pursuant to regulation 33 of the Listing Regulations.

The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed for trading till Thursday, August 14, 2025, and shall reopen on and from Monday, August 18, 2025, for the Directors and Designated Persons.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





The financial results and limited review reports will be available on the website of the Company at www.zyduslife.com.

The Board meeting commenced at 11:50 a.m. and concluded at 12:55 p.m.

Please receive the information and disclosures in order.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZYDUS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ZYDUS LIFESCIENCES LIMITED** ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deloitte Haskins & Sells LLP

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)



Kartikeya Raval

Kartikeya Raval

Partner

(Membership No. 106189)

UDIN: 25106189BMNRLI2544

Place: Ahmedabad

Date: August 12, 2025


Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2025

Sr. No.	Particulars	INR Million			
		Quarter ended			Year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		(Unaudited)	(Unaudited) (Refer Note-3)	(Unaudited)	(Audited)
1	Income				
a	Revenue from operations				
i	Sale of products	24,958	56,335	40,354	145,901
ii	Other operating revenues	925	1,861	1,248	5,262
iii	Total revenue from operations	25,883	58,196	41,602	151,163
b	Other income	1,571	1,854	1,066	6,962
c	Total income	27,454	60,050	42,668	158,125
2	Expenses				
a	Cost of materials consumed	8,537	7,208	7,257	27,871
b	Purchases of stock-in-trade	561	930	587	3,509
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(60)	(1,236)	(464)	(1,211)
d	Employee benefits expense	4,872	4,763	4,244	17,622
e	Finance costs	1,376	1,554	1,154	4,639
f	Depreciation and amortisation expense	1,300	1,280	1,306	5,239
g	Other expenses	6,481	8,296	6,196	28,105
h	Net (gain)/ loss on foreign currency transactions	(362)	508	53	(2,096)
i	Total expenses	22,705	23,303	20,333	83,678
3	Profit before tax (1-2)	4,749	36,747	22,335	74,447
4	Tax expenses				
a	Current tax	896	8,265	5,316	15,825
b	Deferred tax	6	345	11	873
c	Total tax expenses	902	8,610	5,327	16,698
5	Net Profit for the period/ year (3-4)	3,847	28,137	17,008	57,749
6	Other Comprehensive Income (OCI)				
a	Items that will not be reclassified to profit or loss	(2)	108	93	12
b	Income tax effect on above items	12	4	(2)	52
	Total Other Comprehensive Income	10	112	91	64
7	Total Comprehensive Income (5+6)	3,857	28,249	17,099	57,813
8	Paid-up equity share capital (Face value Re. 1/-)	1,006	1,006	1,006	1,006
9	Other Equity				210,895
10	Earnings per share (not annualised for the quarter)				
a	Basic (Rs.)	3.82	27.96	16.90	57.39
b	Diluted (Rs.)	3.82	27.96	16.90	57.39

Notes :

- [1] The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meetings held on August 12, 2025.
- [2] These financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- [3] The figures of the quarter ended March 31, 2025 are balancing figures between audited figures in respect of the full financial year and year to date figures upto the third quarter of the said financial year.
- [4] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
- [5] The Company has one segment of activity viz., "Pharmaceuticals".

By Order of the Board,
For Zydus Lifesciences Limited,


Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Ahmedabad, August 12, 2025



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZYDUS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **ZYDUS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its joint ventures for the quarter ended June 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities listed in the Annexure to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Deloitte
Haskins & Sells LLP**

6. We did not review the interim financial information of 26 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs 50,148 Million For the quarter ended June 30, 2025, total net loss after tax of Rs 1,770 Million for the quarter ended June 30, 2025 and total comprehensive loss of Rs 1,775 Million for the quarter ended June 30, 2025, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results includes the interim financial information of 26 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs 4,256 Million for the quarter ended June 30, 2025, total loss after tax of Rs 269 Million for the quarter ended June 30, 2025 and total comprehensive loss of Rs 269 Million for the quarter ended June 30, 2025, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs 344 Million for the quarter ended June 30, 2025 and total comprehensive income of Rs 319 Million for the quarter ended June 30, 2025, as considered in the Statement, in respect of 4 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For Deloitte Haskins & Sells LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Kartikeya Raval

Kartikeya Raval
Partner

(Membership No. 106189)
UDIN: 25106189BMNRLJ5772

Place: Ahmedabad
Date: August 12, 2025

ANNEXURE TO THE INDEPENDENT AUDITOR'S REPORT:

The Parent

1. Zydus Lifesciences Limited

List of Subsidiaries

1. Sentynl Therapeutics Inc
2. Zydus Animal Health and Investments Limited
3. Zydus Healthcare (USA) LLC
4. Zydus Healthcare Limited
5. Zydus Healthcare Philippines Inc.
6. Zydus International Private Limited
7. Zydus (Lanka) Private Limited
8. Zydus Pharmaceuticals (USA) Inc.
9. Zydus Wellness Limited
10. Zydus Worldwide DMCC
11. Dialforhealth Greencross Limited
12. Dialforhealth Unity Limited
13. Zydus Pharmaceuticals Limited
14. Zydus Strategic Investments Limited
15. Zydus VTEC Limited
16. Zynext Ventures PTE. LTD.
17. Zydus Pharmaceuticals UK Limited
18. Zydus Pharmaceuticals Canada Inc.
19. Zydus Lifesciences Global FZE
20. Viona Pharmaceuticals Inc., USA
21. Violio Healthcare Limited
22. Biochem Pharmaceutical Private Limited
23. Zydus Medtech Private Limited
24. Zydus MedTech (France) SAS (w.e.f. April 10, 2025)
25. German Remedies Pharmaceuticals Private Limited
26. M/s. Recon Pharmaceuticals and Investments
27. Zydus Pharmaceuticals Mexico SA De CV
28. Zydus Pharmaceuticals Mexico Services Company SA De C.V.
29. ZyVet Animal Health Inc [USA]
30. Liva Investment Limited (Under liquidation)
31. Liva Nutritions Limited
32. Zydus Wellness Products Limited
33. Zydus Wellness International DMCC
34. Zydus Wellness BD Private Limited
35. Naturell (India) Private Limited (Under liquidation)
36. Naturell Inc. (USA)
37. Alidac Healthcare Myanmar Limited
38. Etna Biotech S.R.L.
39. Zydus France SAS
40. Zydus Healthcare S.A. (Pty) Ltd.
41. Zydus Netherland B.V
42. Zydus Therapeutics Inc.
43. Script Management Services (Pty) Ltd.
44. Alidac Pharmaceuticals SA (Pty) Ltd.



45. Laboratorios Combix S.L.
46. Zydus Nikkho Farmaceutica Ltda.
47. Zynext Ventures USA LLC, USA
48. LiqMeds Worldwide Limited
49. LiqMeds Limited
50. Medsolutions (Europe) Limited
51. LiqMeds Lifecare Limited
52. LM Manufacturing Limited
53. LM Manufacturing India Private Limited

List of Joint Ventures

1. Zydus Hospira Oncology Private Limited
2. Zydus Takeda Healthcare Private Limited
3. Oncosol Limited
4. Sterling Biotech Limited





Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN : L24230GJ1995PLC025878

Statement of Consolidated Unaudited Financial Results for the Quarter Ended June 30, 2025

Sr. No.	Particulars	INR Million			
		Quarter ended			Year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		(Unaudited)	(Unaudited) (Refer Note-9)	(Unaudited)	(Audited)
1	Income				
a	Revenue from operations				
i	Sale of products	64,670	62,902	60,465	225,738
ii	Other operating revenues	1,067	2,377	1,610	6,677
iii	Total revenue from operations	65,737	65,279	62,075	232,415
b	Other income	1,549	806	632	2,695
c	Total income	67,286	66,085	62,707	235,110
2	Expenses				
a	Cost of materials consumed	12,189	11,644	11,155	43,729
b	Purchases of stock-in-trade	6,582	5,726	5,224	21,500
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(876)	(399)	(518)	(1,849)
d	Employee benefits expense	10,052	9,714	8,835	36,806
e	Finance costs	847	766	322	1,659
f	Depreciation and amortisation expense	2,381	2,379	2,153	9,158
g	Other expenses	17,476	16,945	16,287	63,278
h	Net (gain)/ loss on foreign currency transactions	(571)	394	252	(1,634)
i	Total expenses	48,080	47,169	43,710	172,647
3	Profit before exceptional items, tax and share of profit of joint ventures (1-2)	19,206	18,916	18,997	62,463
4	Exceptional items (Refer Note-4)	-	2,196	-	2,196
5	Profit before tax and share of profit of joint ventures (3-4)	19,206	16,720	18,997	60,267
6	Tax expenses (Refer Note-5)				
a	Current tax	2,307	9,906	6,538	20,493
b	Deferred tax	2,033	(5,674)	(2,177)	(6,374)
c	Total tax expenses	4,340	4,232	4,361	14,119
7	Profit before share of profit of joint ventures (5-6)	14,866	12,488	14,636	46,148
8	Share of profit/ (loss) of joint ventures (net of tax)	344	(51)	189	578
9	Net profit before non-controlling interests (7+8)	15,210	12,437	14,825	46,726
10	Non-controlling interests	542	728	626	1,471
11	Net profit for the period/ year (9-10)	14,668	11,709	14,199	45,255
12	Other Comprehensive Income (OCI)				
a i	Items that will not be reclassified to profit or loss	(31)	106	101	(78)
a ii	Income tax effect on above items	17	6	(2)	73
b i	Items that will be reclassified to profit or loss	88	(322)	(335)	(977)
b ii	Income tax effect on above items	-	-	-	-
c	Share of OCI of joint ventures (net of tax)	(25)	(18)	-	(18)
d	Total Other Comprehensive Income before Non-Controlling Interests	49	(228)	(236)	(1,000)
e	Non-Controlling Interests	-	(2)	-	(2)
f	Total Other Comprehensive Income	49	(226)	(236)	(998)
13	Total Comprehensive Income (9+12 d)	15,259	12,209	14,589	45,726
14	Total Comprehensive Income attributable to:				
	Owners of the Company	14,717	11,483	13,963	44,257
	Non-Controlling Interests	542	726	626	1,469
15	Paid-up equity share capital (Face value Re. 1/-)	1,006	1,006	1,006	1,006
16	Other Equity				238,525
17	Earnings per share (not annualised for the quarter)				
i	Basic (Rs.)	14.58	11.64	14.11	44.97
ii	Diluted (Rs.)	14.58	11.64	14.11	44.97



✍


Segment Information:		INR Million			
Sr. No.	Particulars	Quarter ended			Year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		(Unaudited)	(Unaudited) (Refer Note-9)	(Unaudited)	(Audited)
1	Segment revenue:				
a	Pharmaceuticals	57,162	56,172	53,693	205,439
b	Consumer Products	8,575	9,107	8,382	26,976
c	Total revenue from operations	65,737	65,279	62,075	232,415
2	Segment results:				
a	Pharmaceuticals	17,772	17,196	17,496	58,993
b	Consumer Products	1,434	1,720	1,501	3,470
c	Total profit before tax before exceptional items	19,206	18,916	18,997	62,463
3	Segment assets:				
a	Pharmaceuticals	317,354	307,628	245,502	307,628
b	Consumer Products	63,968	64,389	59,264	64,389
c	Total assets	381,322	372,017	304,766	372,017
4	Segment liabilities:				
a	Pharmaceuticals:	96,479	101,090	64,915	101,090
b	Consumer Products	6,001	7,343	4,242	7,343
c	Total liabilities	102,480	108,433	69,157	108,433

Notes :

- [1] The above consolidated financial results, relate to Zydus Lifesciences Limited [the Parent], its Subsidiaries [together referred as the Group] and Joint Ventures, are prepared by applying Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures".
- [2] The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meetings held on August 12, 2025.
- [3] These financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- [4] Exceptional items comprise:

Sr. No.	Particulars	INR Million			
		Quarter ended			Year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		(Unaudited)	(Unaudited) (Refer Note-9)	(Unaudited)	(Audited)
a	Impairment of Goodwill related to Brazil business	-	1,350	-	1,350
b	Impairment of a product related intangible held by Zydus Worldwide DMCC, a wholly owned subsidiary	-	846	-	846
c	Total	-	2,196	-	2,196

- [5] Deferred tax expense for the quarter ended June 30, 2025 includes net reversal of Minimum Alternate Tax [MAT] credit entitlement amounting to INR 146 Millions by one of the subsidiaries of the Group. Deferred tax expense for the year ended March 31, 2025 includes recognition of MAT credit entitlement amounting to INR 164 Million by one of the subsidiaries of the Group.
- [6] Pursuant to the Share Purchase and Share Subscription Agreement [SPSSA] entered on August 23, 2024, Zydus Animal Health and Investments Limited, a wholly owned subsidiary of the Parent, had completed the acquisition of 50% stake of Sterling Biotech Limited [SBL] on August 29, 2024. Consequently, SBL had become a Joint Venture of the Group w.e.f. August 29, 2024. The cost of acquisition was INR 5,500 Million subject to certain adjustments with respect to cash and debt [including debt like items] as mentioned in the SPSSA. The results include the share of profits of SBL from August 29, 2024.
- [7] Pursuant to the Share Purchase Agreement [SPA] entered into by Zydus Wellness Limited [ZWL], a subsidiary of the Parent, on October 30, 2024, to acquire Naturell (India) Private Limited [NIPL], ZWL had successfully completed the acquisition of NIPL on December 2, 2024. The cost of acquisition was INR 3,900 Million. The same comprises of INR 3,690 Million as upfront consideration and additional consideration of INR 210 Million paid upon the achievement of agreed milestones for the financial year 2024-25. The results include the operations of NIPL from December 2, 2024, with provisional purchase price allocation [PPA] figures. The PPA figures will be finalized within the measurement period, as provided by Ind AS 103.
- [8] On March 11, 2025, the Board of Directors of the Parent had approved entering into a put-option agreement with PAI Partners and two share purchase agreements with two minority shareholders, to acquire, directly or through its affiliates, a controlling stake i.e. 85.6% equity shares ["Block Acquisition"] of Amplitude Surgical SA, France [Amplitude] at a price of Euro 6.25 per equity share aggregating to a consideration value of Euro 256.80 Million [equivalent to INR 23,798 Million]. After conducting the mandatory information and consultation process with the Social and Economic Committee [employee representative body] of Amplitude and obtaining a positive opinion from the said committee and after obtaining approval of French Minister of Economy as part of the control of foreign investments in France, the Parent had signed a share purchase agreement on April 25, 2025 to acquire 75.4% of the share capital of Amplitude from PAI Partners, Olivier Jallabert [CEO of Amplitude] and other managers of Amplitude, which together with the two share purchase agreements already signed on March 11, 2025 with two minority shareholders represent 85.6% of the share capital of Amplitude.
- All the conditions precedent to the completion have been fulfilled and the Block Acquisition has been completed on July 29, 2025. As a result, Zydus MedTech France, SAS [ZMF], a wholly owned subsidiary of the Group, holds 85.6% of the share capital and voting rights of Amplitude. ZMF has filed on July 30, 2025, a simplified mandatory tender offer ["the Offer"] with French Financial Market Authority [Autorité des marchés financiers, "AMF"] for acquiring all the remaining outstanding shares of Amplitude at a price of Euro 6.25 per share, identical to the price paid for the Block Acquisition. Considering the undertaking received from seven shareholders to participate in tender offer representing in aggregate 4.7% of share capital and voting rights, ZMF will be in a position to hold more than 90% of the capital and voting rights of the Amplitude, upon completion of the Offer. Post Offer, for any outstanding shares not tendered through the Offer, ZMF will initiate the process of squeeze-out and delist Amplitude.
- Subject to the clearance of the Offer by AMF, it is currently anticipated that the Offer may be opened in September 2025. No other regulatory approval will be required.



Handwritten initials in blue ink.


[9] The figures of the quarter ended March 31, 2025 are balancing figures between audited figures in respect of the full financial year and year to date figures upto the third quarter of the said financial year.

[10] Figures of previous reporting periods/ year have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting periods.

[11] The detailed standalone results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com]. The summarised standalone financial results of the Company are as below:

Particulars	INR Million			
	Quarter ended			Year ended
	30/06/2025	31/03/2025	30/06/2024	31/03/2025
	(Unaudited)	(Unaudited) (Refer Note-9)	(Unaudited)	(Audited)
Revenue from operations	25,883	58,196	41,602	151,163
Profit before Tax	4,749	36,747	22,335	74,447
Profit after Tax	3,847	28,137	17,008	57,749

By Order of the Board,
For Zydus Lifesciences Limited,



Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Ahmedabad, August 12, 2025

